Table 1.
Clinicopathological features and PET/CT parameters in study
| Characteristics | EGFR Mutant | EGFR Wild | Total | p value |
|---|---|---|---|---|
| Age (years, median) | 63 | 64.5 | 64 (37-85) | 0.767 |
| Gender | ||||
| Male/Female | 16/21 | 26/12 | 42/33 | 0.037 |
| Non-smoking | 26 (66.67%) | 13 (33.33%) | 39 (52%) | 0.003 |
| Primary tumor size (cm, median) | 3.8 | 3.2 | 3.5 | 0.979 |
| Regional node involvement | 25 (53.19%) | 22 (46.81%) | 47 (63%) | 0.476 |
| Bone metastasis | ||||
| Oligo (<5) | 12 (46.15%) | 14 (53.85%) | 26 (35%) | 0.809 |
| Multiple (≥5) | 25 (51.02%) | 24 (48.98%) | 49 (65%) | |
| Other distant organ metastasis | 8 (42.11%) | 11 (57.89%) | 19 (25.33%) | 0.597 |
| Interval between bone biopsy and PET/CT (day, median) | 6 | 4 | 5 | 0.175 |
| pSUVmax (median) | 7.7 | 8.5 | 8.3 | 0.454 |
| nSUVmax (median) | 6.6 | 5.6 | 6.4 | 0.208 |
| bmSUVmax (median) | 7.7 | 9.7 | 8.9 | 0.015 |
| CK7 | 75 (100%) | |||
| Positive | 37 (50.68%) | 36 (49.32%) | 0.493 | |
| Negative | 0 | 2 (100%) | ||
| Vilin | 72 (96%) | |||
| Positive | 11 (42.31%) | 15 (57.69%) | 0.469 | |
| Negative | 24 (52.17%) | 22 (47.83%) | ||
| TTF-1 | 75 (100%) | |||
| Positive | 35 (60.34%) | 23 (39.26%) | 0.001 | |
| Negative | 2 (11.76%) | 15 (88.24%) | ||
| NaspinA | 75 (100%) | |||
| Positive | 34 (59.65%) | 23 (40.35%) | 0.002 | |
| Negative | 3 (16.67%) | 15 (83.33%) | ||
| Ki67 | 55 (73%) | |||
| >20% | 12 (50%) | 12 (50%) | 0.789 | |
| ≤20% | 14 (45.16%) | 17 (54.84%) |